REGN2810 in Pediatric Patients With Relapsed, Refractory Solid, or Central Nervous System (CNS) Tumors and Safety and Efficacy of REGN2810 in Combination With Radiotherapy in Pediatric Patients With Newly Diagnosed or Recurrent Glioma
Stopped Sponsor Decision
Conditions
- Relapsed Solid Tumor
- Refractory Solid Tumor
- Relapsed Central Nervous System Tumor
- Refractory Central Nervous System Tumor
- Diffuse Intrinsic Pontine Glioma
- High Grade Glioma
Interventions
- DRUG: cemiplimab (monotherapy)
- DRUG: cemiplimab (maintenance)
- RADIATION: Conventional or hypofractionated
- RADIATION: Re-irradiation
Sponsor
Regeneron Pharmaceuticals
Collaborators